Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

Autor: Paolo Maria Matricardi, Ludger Klimek, Thomas B. Casale, Oliver Pfaar, Miguel Tortajada-Girbés, Ignacio J. Ansotegui, Cristoforo Incorvaia, Pascal Demoly, Marek Jutel, Petra Zieglmayer, Maximiliano Gómez, Philippe Devillier, Philippe Gevaert, Jean Bousquet, Petr Panzner, Giorgio Walter Canonica, Mona Al-Ahmad, Ralph Mösges, Stefania Arasi, Alain Didier, Piotr Kuna, Carmen Vidal, Peter Schmid-Grendelmeier, Carla Irani, Oxana Kurbacheva, Moises A. Calderon, Frédéric de Blay, Ulrich Wahn, Enrico Heffler, Alessandro Fiocchi, Adam T. Fox, Hae-Sim Park, Ruby Pawankar, Davide Caimmi, Claus Bachert, Natalija Novak, Margitta Worm, Nikolaos G. Papadopoulos, Silvia Scurati, Andrzej Bozek, Mário Morais-Almeida, Giovanni Passalacqua, Catherine Bos, Yoshitaka Okamoto, Natalia Ilina, Efstrathios Karagiannis, Robin O'Hehir, J. Christian Virchow, Adnan Custovic
Přispěvatelé: ASST Pini-CTO, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Hospital Quirónsalud Bizkaia [Bilbao], Bambino Gesù Children’s Hospital [Rome, Italy], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Stallergenes Greer (France, Antony), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Silesian Medical University, Katowice, Poland, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, University of South Florida [Tampa] (USF), University of Manchester [Manchester], University Hospital of South Manchester, CHU Strasbourg, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université de Montpellier (UM), Hôpital Foch [Suresnes], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Guy's and St Thomas' Hospital [London], Hospital San Bernardo, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Humanitas University [Milan] (Hunimed), Federal Institute of Immunology of Russia [Moscou], Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Wrocław Medical University, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Barlicki University Hospital, Medical University of Łódź (MUL), Monash University [Melbourne], Federal Medical-Biological Agency of Russia, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Hospital CUF Descobertas, University of Cologne, University Hospital Bonn, Chiba University Hospital, Charles University [Prague] (CU), Royal Manchester Children's Hospital, General Children's Hospital of Athens P & A Kyriakou, Ajou University School of Medicine, Ospedale Policlinico San Martino [Genoa], Università degli studi di Genova = University of Genoa (UniGe), Nippon Medical School [Tokyo, Japan], Philipps Universität Marburg = Philipps University of Marburg, University hospital of Zurich [Zurich], Dr Peset University Hospital, Universitat de València (UV), Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), University of Rostock, Herrada, Anthony, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], Wroclaw Medical University [Wrocław, Pologne], University of Genoa (UNIGE), Philipps Universität Marburg
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Allergy
Allergy, 2021, 76 (4), pp.1041-1052. ⟨10.1111/all.14575⟩
Allergy, Wiley, 2021, 76 (4), pp.1041-1052. ⟨10.1111/all.14575⟩
ALLERGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
ISSN: 0105-4538
1398-9995
Popis: International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.
Databáze: OpenAIRE
Externí odkaz: